- Day 2 - Saturday, 2 March
- Pediatric Rheumatology Meeting
07:30 - 08:30 | Registration | ||
08:30 - 08:45 | Welcome Remarks | ||
Session 1: Spondyloarthritis (SpA) | |||
08:45 - 09:10 | Recommendations on Early Diagnosis and Referral of Axial Spondyloarthritis (axSpA) | Hanan Alrayes | |
09:10 - 09:35 | Predictors of not Achieving Remission or Low Disease Activity in Axial Spondyloarthritis (axSpA) | Ahmed Negm | |
09:35 - 10:00 | Recommendations for the Management of Spondyloarthritis (SpA) Patients from Kuwait | Adeeba Al-Herz | |
10:00 - 10:15 | Difficult Spondyloarthritis (SpA) Cases | Priyanka Moovara Cackamvalli | |
10:15 - 10:35 | Panel Discussion | ||
10:35 - 11:05 | Industry Symposium by Novartis | Maisam Musgrave | |
11:05 - 11:25 | Coffee Break & Poster Viewing Session | ||
11:25 - 11:55 | Industry Symposium by AbbVie | Ahmed Zayat | |
Session 2: Rheumatology & Central Nervous System (CNS) | |||
11:55 - 12:35 | Lupus, Hughes Syndrome & the Brain | Graham Hughes | |
12:25 - 12:40 | Cracking the Code: Navigating the Challenges of Neuropsychiatric Lupus | Deena Shaheen | |
12:40 - 12:55 | Primary Central Nervous System (CNS) Vasculitis: Untangling the Diagnostic Quandary | Abdullatif Almehaideb | |
12:55 - 13:10 | Panel Discussion | ||
13:10 - 15:15 | Lunch | ||
Session 3: Systemic Lupus Erythematosus (SLE) | |||
15:15 - 15:45 | Industry Symposium by NewBridge | Karl Gaffney | |
15:45 - 16:25 | Lupus Nephritis in the Gulf | Munther Khamashta | |
16:25 - 16:40 | Digital Ischemia and Dry Gangrene as First Manifestation of Systemic Lupus Erythematosus (SLE) | Khalid Abdulrahman Altalhi | |
16:40 - 17:00 | Diving Deep into Lupus: Gastrointestinal Involvement Insights from the Oman Lupus Study | Nasra Al Adhoubi | |
17:00 - 17:15 | Subconjunctival Hemorrhage as an Initial Presentation of Systemic Lupus Erythematosus (SLE) | Jawaher Enani | |
17:15 - 17:35 | Panel Discussion | ||
17:35 - 18:05 | Industry Symposium by GSK | Mohamed Gamal | |
*This program is subject to change without prior notice. Program as of 27 February 2024
07:00 - 08:00 | Registration | ||
08:00 - 08:05 | Welcome Remarks | Ayesha AlMheiri | |
Session 1: Genetics and Autoinflammatory Moderator: Elsadeg Sharif |
|||
08:05 - 08:35 | Role of Genetics in Pediatric Rheumatology | Maryam AlShehhi | |
08:35 - 09:05 | Autoinflammation and Immunology: Bridging the Gaps | Shuayb Elkhalifa | |
09:05 - 09:35 | Childhood Vasculopathy: New Insights | Sulaiman Al-Mayouf | |
09:35 - 09:50 | Coffee Break | ||
Session 2: Juvenile Rheumatoid Arthritis (JIA) Moderator: Wafa Madan |
|||
09:50 - 10:20 | Screening Prior Initiation of Biologic Treatment | Hend Alkwai | |
10:20 - 10:50 | Choice and Switch of Biologic Therapy in Juvenile Rheumatoid Arthritis (JIA) | Ayesha AlMheiri | |
10:50 - 11:20 | Updates on Management of Uveitis in Children and Adolescent | Francesco Pichi | |
11:20 - 11:50 | Secondary Osteoporosis in Children & Adolescents | Mohamed Zulficar Mughal | |
11:50 - 12:05 | Coffee Break | ||
Session 3: Childhood Onset Lupus Moderator : Nora Al Mutairi |
|||
12:05 - 12:35 | Childhood Lupus in Gulf: Are we Different? | Eman Al Masroori | |
12:35 - 13:05 | Biomarkers in Lupus: Clinical Implications | Najla Aljaberi | |
13:05 - 14:20 | Lunch | ||
Session 4: Oral Abstracts and Challenging Cases Moderator: Reem Abdwani |
|||
14:20 - 14:40 | First Case Report of Omani Child with PRKCD Mutation with Monogenic Systemic Lupus Erythematosus (SLE) | Amani Al Ghadani | |
14:40 - 15:00 | Rare and Fatal Interstitial Lung Disease (ILDs) as Complication of Systemic Juvenile Rheumatoid Arthritis (JIA) | Ikram Shaalan | |
15:00 - 15:20 | STAT1 GOF Immundysregulation: A Case Report with CMC, Polyendocrinopathy, and Arthritis; Highlighting on the Efficacy of Adalimumab | Reima Bakry | |
15:20 - 15:40 | Early Recognition, Multidisciplinary Approach, and Mortality Prevention: A Case of Macrophage Activation Syndrome at Presentation in a New Onset Juvenile Systemic Lupus Erythematosus (SLE) | Bushra Abu Saleh | |
15:40 - 16:00 | Progressive Pseudo Rheumatoid Dysplasia Misdiagnosed as Juvenile Idiopathic Arthritis (JIA): Case Presentation | Duaa Hafiz | |
*This program is subject to change without prior notice. Program as of 27 February 2024